CPRIT Awards $6 Million for Research at UT Southwestern and UT Dallas

The Cancer Prevention and Research Institute of Texas is awarding $6 million worth of grants to North Texas cancer researchers in the first round of funding since the organization was backed by voters in the November elections. UT Southwestern and UT Dallas both recruited researchers with the help of CPRIT funds. The funding was part of $38 million for 10 research grants to bring the total number of CPRIT scholars to 192 across the state. “As overwhelmingly affirmed earlier this month, voters want Texas to be the center of world-class cancer research,” said Wayne Roberts, CPRIT Chief Executive Officer via… Full Story

Eosera Doubles Its Footprint in Fort Worth

Eosera, Inc., the biotech company that specializes in product ear-treatment will expand to a larger facility in Fort Worth by the end of this month. Eosera’s founder and CEO, Elyse Dickerson hopes the larger space will benefit the company’s increasing consumer demand for their ear-care products. The expansion doubles the size of the company’s warehouse and manufacturing space, where all manufacturing of Eosera’s products are done. The growth arrives with the addition of two new products. “The main driver is expansion of retail distribution and expansion of our product line. So because of both of those, we’ve had to increase our production of… Full Story

CPRIT Awards $15.4 Million to OncoNano For HPV-Caused Cancer Treatment

Southlake’s OncoNano Medicine, Inc. has been awarded $15.4 million to continue to develop one of its cancer treatment candidates. The funding is from the Cancer Prevention and Research Institute of Texas will go toward pre-clinical and clinical development as well as the first phase of a trial for cancer caused by the human papilloma virus. The treatment is called ONM-500, which delivers antigens while engaging the immunity that already exists in the human body, fighting cervical, head, and neck cancers caused by HPV. CPRIT, which has awarded $2.4 billion in grants to Texas research, has funded the product which was first… Full Story

Local Biotech Company Expands National Retail Footprint with Ear Care Product

Biotech ear care company Eosera is expanding into Rite Aid stores after Amazon and CVS picked up the products. Earwax MD and Ear Pain MD are over-the-counter products targeting the millions of people who suffer from earwax impaction and ear pain. While earwax naturally accumulates, it can be impacted if it hardens within the the ear canal, which can result in pain and hearing loss. Six percent of the global population suffers from earwax impaction, including up to 10 percent of children and 65 percent of seniors over 65, according to the National Institutes of Health. In the US, 12… Full Story

We May Have Lost Amazon, But Biotech Could Be Dallas’ Next Big Move

While no doubt a disappointment, Amazon’s decision to locate its second headquarters in New York and Virginia doesn’t diminish the economic vitality of North Texas. In fact, Dallas’ strong showing in the company’s high-profile national search bolsters our reputation as an attractive region for business. Now, as we take stock of the Amazon decision and explore new ways to grow the local economy, let’s consider the potential of an untapped community asset: biotechnology. Dallas is well-known for its oil industry, corporate headquarters, and technology startups. But did you know that the science behind some of the best-selling prescription drugs of all… Full Story

Before Babies Are Born, This Surgeon Operates On Them

The best place for a baby to recover from surgery is the womb. So, when fetuses need surgery, the best place to operate is in utero. Dallas is home to one of the top fetal surgeons in the country, Dr. Timothy Crombleholme, who opened The Fetal Care Center at Medical City Dallas this summer. Shawn Shinneman’s October D Magazine piece chronicles Crombleholme’s path to Dallas, the development of fetal surgery locally, and the story of a North Texas family whose twin children required an operation while they were inside their mother’s womb. The Fetal Care Center is just one of… Full Story

Medical City Plano Adds Single-Dose Radiation For Breast Cancer Patients

A new treatment at Medical City Plano is reducing breast cancer treatment from eight weeks to eight minutes. For early-stage breast cancer patients, the new procedure involves surgery and radiation using iCAD’s Xoft Electronic Brachytherapy System. The FDA-approved treatment uses a miniaturized x-ray to deliver a precise, concentrated dose of radiation to a tumor site directly after surgery, or lumpectomy. The radiation treats the remaining tumor that wasn’t removed during the surgery. The treatment isn’t limited to breast cancer, but can be used for non-melanoma skin cancer and gynecological cancer as well. Worldwide, more than 10,000 patients have been successfully treated.… Full Story

A Health Reporter Has a Tale of a Mystery Fire Alarm During a Theranos-related Reporting Trip

About a year before the Wall Street Journal started a firestorm for then-biotech darling Theranos, one reporter had an experience with the company—which has a Dallas tie through real estate developer Craig Hall, who is an investor—that might’ve warned of the troubles ahead. Kaiser Health News‘ Jenny Gold has a piece out this week about her run in with the company in late 2014, while reporting a story for NPR. After meeting Theranos’ press representatives at Theranos-partner Walgreens, the reps became nervous about the type of questions Gold was asking patients. Gold was curious as to why they all seemed to… Full Story

The State’s CPRIT Program Comes with Risk, But One of Its Top Dogs is Optimistic

Since the state of Texas put $3 billion behind the Cancer Prevention Research Institute of Texas (CPRIT) a decade ago, much of the news coming out has been less than flattering. After lawmakers questioned potential conflicts of interest at the program, state auditors discovered issues with regard to the way a small portion of the grants associated with the $3 billion fund were handed out. Not a good look, to be sure, but the taxpayers who’d originally backed the institute might have found it easier to move past the problems had the news been balanced by, say, the development of… Full Story